After a year of development, we are proud to introduce the Mitochondrial Platform, which has reduced research time by an impressive 300 days. Our platform is now operational and offers comprehensive research on mitochondrial disorders, as well as studies on neurodegenerative diseases and oncology.
Reflecting on this year of development and our challenges in reaching out to patients worldwide, we have built a supportive community. Parents have expressed heartfelt support for our efforts, often sharing concerns that, while our work may ultimately benefit future generations, their children participating in the research may not see immediate gains.
Our commitment to overcoming any challenges that might prolong the research process is unwavering. The efficiency of our platform has significantly improved, saving the equivalent of 300 days. It took a year to establish our processes, build the supply chain, develop models, and collect the necessary data to reach this milestone. Additionally, we spent years developing the Stemnovate Platform, which has helped us demonstrate our capabilities.
From the day of consent, we facilitate participation across countries and borders while ensuring compliance with country-specific regulations. We provide specialized cell models, including functional neurons, heart, and liver cells. Our multi-omics approach offers deep insights derived from actual cell studies and gene and protein expression data. This involves thorough bioinformatics, whole genome sequencing, cell modelling, functional analysis, reproducibility, and unbiased data analysis.
We have been observing genetic and mitochondrial changes and often receive requests from parents to understand what these changes mean for their children. While there are no simple answers to this question, we are hopeful that by continuing to study these alterations within the context of cellular pathways and functions, we can explore new treatment, management, or therapy paths. We also assist multiple companies in testing new drug molecules to develop effective treatments.
It is important to share our journey, as many partners and team members work together to overcome challenges and make this possible. If you're interested, please get in touch with us to discuss how we can expedite your mitochondrial research journey toward a successful clinical application.
If you or a family member has a rare disease, neurodegenerative disorder, or liver-related condition, you can participate in our research.
Please note that we are not a charity or not-for-profit organization and do not solicit donations. Instead, we operate a commercial platform to help pharmaceutical companies and academic institutions conduct research more efficiently and effectively. Its commercial nature ensures our sustainability and ability to continue our important work.